AL Amyloidosis Background
Every protein has an assigned job, a schedule, and a freshly pressed lab coat. Antibodies clock in, fight infections, and clock out when their job is done. But what happens when one of those antibodies becomes unmoored—cutting corners, breaking rules, or acting outside its assigned role? That's when light chain AL amyloidosis can develop. Light chain AL amyloidosis is a rare and often underdiagnosed medical condition, characterized by multiorgan deposition of misfolded immunoglobulin light-chain amyloid fibrils that cause mechanical disruption, local oxidative stress, and eventual organ failure.¹ The most involved organs are the heart and kidneys, but the gastrointestinal tract, liver, and nerves may also be involved. The clinical presentation of AL amyloidosis often includes fatigue and unintentional weight loss but may also include additional symptoms specific to the organs involved.²⁻⁴
References
-
Baker KR. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication. Methodist Debakey Cardiovasc J. 2022;18(2):27-35. Published 2022 Mar 14.
-
Al Saleh As, Sidiqi Mh, Muchtar E, Et Al. Outcomes Of Patients With Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation With 3 Or More Organs Involved. Biology Of Blood And Marrow Transplantation: Journal Of The American Society For Blood And Marrow Transplantation. 2019;25(8):1520-1525.
-
Ashutosh Wechalekar, Alberico Del Torto, Quarta C, Liedtke M. Al Amyloidosis For Cardiologists. Jacc: Cardiooncology. 2022;4(4):427-441.
